MicroRNA Market Size & Outlook, 2026-2034

MicroRNA Market Overview

The global microRNA market size is estimated at USD 1.96 billion in 2025 and is projected to reach USD 5.75 billion by 2034, growing at a CAGR of 12.72% during the forecast period. The remarkable market growth is attributed to the increasing integration of AI-driven microRNA pattern analysis tools for diagnostic precision.

Key Market Trends & Insights

• North America dominated the global market, accounting for a 42.06% share in 2025.
• The Asia Pacific region is projected to grow at the fastest pace, with a CAGR of 14.10% during the forecast period.
• Based on products & services, the services segment held the highest market share in 2025.
• By application, the infectious diseases segment is projected to register the fastest CAGR growth of 13.61% during the forecast period.
• By end use, the biotechnology & pharmaceutical companies segment dominated the market in 2025, accounting for 46.19% revenue share.
• The U.S. dominates the market, valued at USD 663.48 million in 2024 and reaching USD 745.02 million in 2025.

Table: U.S. MicroRNA Market Size (USD Million)

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 1.96 billion
• 2034 Projected Market Size: USD 5.75 billion
• CAGR (2026-2034): 12.72%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

The microRNA market encompasses comprehensive products and services that support the detection, analysis, and functional study of miRNAs across diverse biomedical applications. It includes specialized services such as miRNA profiling, localization, quantification, cDNA synthesis, purification, and functional analysis, alongside instruments and consumables designed for advanced molecular workflows. These solutions are widely utilized in cancer, infectious, immunological, cardiovascular, neurological, and other disease research, serving biotechnology and pharmaceutical companies, academic institutions, government research bodies, and related end users.

Latest Market Trends

Growing Integration of Liquid Biopsy-based Mirna Diagnostics

A key trend shaping the microRNA market is the rapid adoption of liquid biopsy technologies for non-invasive miRNA detection. Advancements in circulating miRNA profiling enable earlier diagnosis, real-time disease monitoring, and improved therapeutic decision-making across oncology and chronic disorders. This shift reflects increasing clinical demand for minimally invasive diagnostic tools that enhance precision medicine, expand screening capabilities, and address limitations of conventional tissue-based diagnostic approaches.

Accelerating Clinical Validation of Mirna-based Therapeutics

A major trend in the microRNA market is the growing momentum toward clinical validation of miRNA-based therapeutics, driven by advancements in RNA modulation technologies and targeted delivery systems. Increasing progression of miRNA mimics and inhibitors into early- and mid-stage clinical trials reflects rising confidence in their therapeutic potential across oncology, metabolic disorders, and rare diseases. This trend underscores expanding investment, stronger regulatory engagement, and the emergence of miRNA therapies as a transformative class within precision medicine.

To get more insights about this report Download Free Sample Report

Market Drivers

Increasing Adoption of Mirna Biomarkers In Early Disease Detection

The rising clinical adoption of miRNA biomarkers for early and precise disease diagnosis. As conditions such as cancer, cardiovascular disorders, and neurological diseases continue to grow worldwide, healthcare systems are prioritizing highly sensitive diagnostic tools. For instance, various oncology programs have incorporated circulating miRNA panels to improve early tumor detection and treatment monitoring.

This shift toward biomarker-based diagnostics is accelerating demand for advanced miRNA assays, profiling platforms, and analytical solutions, thereby propelling market growth.

Market Restraints

Complexity of Mirna Therapeutic Development and Delivery Systems

A major restraint in the microRNA market is the scientific and technical complexity associated with developing safe and effective miRNA based therapeutics. Challenges such as ensuring target specificity, preventing off-target gene modulation, and achieving stable in-vivo delivery increase development timelines and cost. For example, several miRNA mimic candidates have faced clinical delays due to delivery inefficiencies and safety concerns. These obstacles slow therapeutic advancement, limit commercial scalability, and hinder broader adoption of miRNA-driven interventions.

Market Opportunity

Expanding The Potential of Mirna-Based Companion Diagnostics

The rising development of miRNA-based companion diagnostics that support personalized treatment decisions is a key opportunity for market growth. As precision medicine grows, pharmaceutical companies are increasingly integrating miRNA signatures to predict therapeutic response and optimize clinical outcomes. For example, emerging oncology programs are using circulating miRNA panels to identify patients likely to benefit from targeted therapies. This advancement enhances treatment accuracy, strengthens drug diagnostic partnerships, and opens new avenues for market expansion.

Regional Analysis

North America dominated the MicroRNA market in 2025, accounting for 42.06% market share, owing to the substantial federal investment in RNA, genomics, and precision medicine programs. Initiatives supported by agencies such as the NIH and NSF expand advanced research infrastructure, accelerate translational discovery, and strengthen institutional capacity, creating a high-growth environment for miRNA technologies across academic and commercial sectors.

In Canada, the launch of Genome Canada led Canadian Precision Health Initiative, which invests heavily in building a nationwide genomic database of over 100,000 genomes. This large-scale genomic data infrastructure enables broader population-level miRNA research, accelerates biomarker discovery, and strengthens Canada’s role in precision medicine and miRNA based diagnostics.

Asia Pacific Market Insights

Asia Pacific is emerging as the fastest-growing region with a CAGR of 14.10% from 2026-2034. The region benefits from rising public-private R&D investment directed at genomics and precision medicine infrastructure. Governments across China, India, Japan, and Southeast Asia are funding genome sequencing centers and bioinformatics hubs, which, in turn, boost the adoption of miRNA diagnostics and research tools across the Asia Pacific.

China microRNA market is expanding rapidly, driven by the steep reduction in sequencing and genomic analysis costs achieved through locally developed instruments and streamlined workflows. As domestic firms optimize technologies and bioinformatics pipelines, miRNA based tests and research become much more affordable and accessible across biopharma and academic institutions.

Regional Market share (%) in 2025

Source: Straits Research

Europe Market Insights

Europe's market growth is driven by the region’s abundant, skilled workforce in molecular biology, bioinformatics, and precision medicine. This deep talent base enables advanced miRNA assay development, complex data analysis, and rapid translation from bench to clinic, strengthening Europe’s competitive edge in miRNA research and commercialization.

Germany's microRNA market growth is driven by the launch of its genomDE national genomics strategy, which builds a standardized platform for genome‑wide sequencing, data integration, and personalized medicine across the country. This coordinated framework enhances miRNA research translation, supports biomarker-driven diagnostics, and attracts biotech investment, strengthening Germany’s leadership in RNA based innovation

Latin America Market Insights

Latin America MicroRNA market growth is supported by the rising burden of infectious diseases, such as dengue, chikungunya, and tuberculosis, which is prompting widespread adoption of molecular diagnostics. As public health systems expand real‑time PCR and next generation sequencing capacity, demand grows for sensitive miRNA based assays capable of early detection, disease monitoring, and pathogen profiling, boosting market growth.

In Brazil, the microRNA market is strengthened by the increasing integration of precision medicine and genomic diagnostics into the public health system. National initiatives such as Genomas Brasil are funding large-scale genomics and genetic testing programs, prompting greater demand for miRNA based assays and personalized diagnostic tools across healthcare and research institutions.

Middle East and Africa Market Insights

Middle East and Africa are witnessing steady market expansion, supported by the growing emphasis on genetic disease screening and population-specific genomics initiatives. Increasing investment in national programs such as the Saudi Genome Program and expanding sequencing facilities in South Africa is driving demand for miRNA based assays and molecular diagnostics tailored to local genetic profiles.

In Saudi Arabia, the microRNA market is driven by the substantial and sustained national investment in biotechnology and genomics under the Saudi Biotechnology Strategy 2040. With the government committing to invest up to 2.5% of GDP in R&D through 2040, this initiative strengthens infrastructure, supports gene‑ and RNA‑based research, and encourages development of miRNA diagnostics and therapies within the Kingdom.

Product & Services Insights

The services segment dominated the market in 2025. This growth is driven by the rising demand for ultra-high resolution single cell miRNA analysis services. These specialized platforms enable precise cellular-level expression profiling, supporting advanced research programs and accelerating discovery workflows that require capabilities beyond conventional laboratory infrastructure.

The products segment is anticipated to witness the fastest growth, registering a CAGR of 13.25% during the forecast period. This growth is supported by the emergence of next-generation microfluidic miRNA isolation instruments. These compact platforms enable automated, contamination-free extraction with higher yield and precision, driving strong demand for advanced products that enhance workflow efficiency in research and clinical laboratories.

Disease Type Insights

The allergies segment accounted for the largest market share of 36.87% in 2025. This dominance is attributed to a rise in ocular hypersensitivity cases linked to rising urban air pollution and prolonged digital screen exposure, which intensify allergic conjunctivitis cases. Additionally, increasing adoption of antihistamine mast cell stabilizer formulations providing rapid and sustained relief has strengthened treatment outcomes, which also support the segment growth.

The glaucoma segment is projected to register the fastest CAGR growth of 9.83% during 2026-2034, owing to increasing prevalence of glaucoma worldwide, rising awareness of early disease diagnosis, and the growing adoption of advanced therapeutics such as prostaglandin analogs, beta blockers, and combination therapies that effectively manage intraocular pressure and slow disease progression.

By Application Market Share (%), 2025

Source: Straits Research

End Use Insights

The biotechnology & pharmaceutical companies segment dominated the market in 2025 with a revenue share of 46.19% in 2025. This growth is attributed to the rising incorporation of miRNA-based target discovery platforms within drug development pipelines. These tools enable pharma and biotech companies to identify novel therapeutic pathways more efficiently, accelerating R&D productivity and strengthening their competitive positioning in precision medicine innovation.

The academic & government research institutes segment is expected to witness the fastest CAGR growth during the forecast timeframe, due to a surge in publicly funded multi-omics infrastructure programs that integrate dedicated miRNA research cores. These initiatives provide advanced analytical resources to academic scientists, accelerating discovery output and expanding institutional capabilities in RNA biology and translational research.

Competitive Landscape

The global microRNA market is moderately fragmented, with leading biotechnology and pharmaceutical firms holding notable shares. Key players, including Thermo Fisher Scientific, QIAGEN, Illumina, Bio‑Rad Laboratories, and NanoString Technologies, are enhancing their market positions through strategic acquisitions, collaborations, advanced miRNA profiling platforms, and R&D investments. Emphasis on innovative assay development, expanded service offerings, and global market penetration strengthens competitiveness in the market.

ARTHEx Biotech: An Emerging Market Player

ARTHEx Biotech, a European biotechnology company, is emerging in the market with a focus on novel therapies for neuromuscular disorders. The company’s lead candidate, ATX-01, is an antisense oligonucleotide targeting miRNA dysregulation in myotonic dystrophy type 1. In 2024, ATX-01 entered Phase 1/2 clinical trials, demonstrating promising safety and preliminary efficacy. With ongoing R&D and strategic collaborations, ARTHEx is positioning itself as an innovative player in the miRNA therapeutic space.

List of key players in MicroRNA Market

1. BioGenex
2. Bio-Techne Corporation
3. GeneCopoeia, Inc.
4. Abcam plc
5. Horizon Discovery Group plc.
6. InteRNA Technologies B.V.
7. LGC Limited
8. Merck KGaA
9. Mirna Therapeutics, Inc.
10. NanoString Technologies, Inc.
11. New England Biolabs
12. PerkinElmer, Inc.
13. QIAGEN
14. Takara Bio, Inc.
15. Thermo Fisher Scientific, Inc.
16. Synlogic, Inc.
17. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• October 2025: PrecisionRNA Biotech Pvt Ltd. launched a Cantel, a microRNA based blood test for breast cancer screening.
• October 2025: Mirxes received approval for its flagship product, GASTROClear, a first non-invasive blood test for gastric cancer screening in China.